tiprankstipranks
Editas Medicine, Genevant Sciences enter collaboration and license agreement
The Fly

Editas Medicine, Genevant Sciences enter collaboration and license agreement

Editas Medicine (EDIT) and Genevant Sciences announced that they have entered into a collaboration and nonexclusive license agreement to combine Editas Medicine’s CRISPR Cas12a genome editing systems with Genevant’s proprietary LNP technology in the development of in vivo gene editing medicines directed to two undisclosed targets in Editas’ upregulation strategy. Under the terms of the agreement, Genevant has granted to Editas a nonexclusive worldwide license under certain Genevant LNP technology to exploit mRNA-CRISPR Cas12a-LNP products directed to two undisclosed targets for specified fields. Genevant is eligible to receive up to $238M in upfront and contingent milestone payments, as well as tiered royalties on future product sales.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App